Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat

This article was originally published in The Pink Sheet Daily

Executive Summary

H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.


Related Content

Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million
Venture Prepares for Structured Acquisitions
Sonus, OncoGenex Merge Into Specialty Oncology Company
Apollo Endosurgery Inc.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts